adipiplon Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Adipiplon is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.   Wikipedia

Chemistry

  • SMILES: CCCc1c(Cn2ccnc2c3ncccc3F)ncn4nc(C)nc14
  • InChIKey: UAMAIHOEGLEXSV-UHFFFAOYSA-N
  • Mol. Mass: 351.39
  • ALogP: 2.83
  • ChEMBL Molecule:
    adipiplon  
More Chemistry

Pharmacology

Alternative names

7-((2-(3-fluoropyridin-2-yl)-1h-imidazol-1-yl)methyl)-2-methyl-8-propyl-(1,2,4)triazolo(1,5-c)pyrimidine | adipiplon | apiplon | ng2-73

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Sleep Initiation and Maintenance Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue